

Supplementary Materials

Dornase Alfa as a Potential Treatment Option for SARS-CoV-2: In Vitro Insights

SUPPLEMENTARY TABLES


Supplementary Table 1. The formulation of Qdots-E3

Formulation	Hydrodynamic size	nm Numeric	% PDI	m ² /sn Diffraction. coeff.	Mv Zeta \mp	$\frac{\mu\text{cm}}{\text{VS}}$ Elektroforethic mobility	mS/cm conductance
E3	6,04	0,42	32,3	81,2			
	4,86	1,95	32,3	101,0	-4,30,6	-0,3339	8,421
	4,86	0,45	30,9	100,9			


Supplementary Table 2. The immune response in PBMC cells treated with different concentration of dornase alfa and viral peptide mix was examined by CBA assay after 72h CBA was performed.

Deney Grupları	IL10 (pg/ml)	IL17 (pg/ml)	IL6 (pg/ml)	IFN γ (pg/ml)	TNF α (pg/ml)
3U DA + Peptit + PBMC	120,046 \pm 117,77	36,969 \pm 8,34	455,121 \pm 145,23	261,429 \pm 193,89	144,339 \pm 192,74
10U DA + Peptit + PBMC	149,539 \pm 68,70	113,892 \pm 126,86	579,786 \pm 151,31	524,442 \pm 441,88	65,401 \pm 62,61
Peptit+PBMC	46,863 \pm 2,33	85,193 \pm 26,26	139,052 \pm 102,29	1044,948 \pm 869,66	120,689 \pm 143,08
Only PBMC	42,673 \pm 2,98	43,124 \pm 25,39	279,891 \pm 222,44	357,071 \pm 321,98	133,504 \pm 86,64

SUPPLEMENTARY FIGURES



Supplementary Figure 1. Transmission Electron Microscopy Imaging of QDots-E3



Supplementary Figure 2. Following treatment of 100X TCID50 SARS-CoV-2 with different concentration of dornase alfa, whole genome sequencing analysis of viral RNA was performed. The lines show the coverage profile after none or 30U dornase alfa incubation